- Enter aldosterone, its unit, and the assay method (immunoassay or liquid chromatography-tandem mass spectrometry, LC-MS/MS). Thresholds differ by method.
- Choose how renin was reported: plasma renin activity (PRA) in ng/mL/h or direct renin concentration (DRC) in mU/L. Keep the reported units; PRA and DRC are not interchangeable. If the result was reported as below the laboratory’s limit (for example “<0.2”), enter the limit and tick the box.
- Add potassium, eGFR, and medication context. These do not change the arithmetic, but they change what the result can and cannot tell you.
- The output describes the screening pattern against the 2025 Endocrine Society values and suggests what to discuss next. It does not diagnose, stop drugs, or route to surgery. Use your laboratory’s validated cut points when they exist.
All computation runs in your browser; no values are stored or transmitted.
When to Use
The 2025 Endocrine Society guideline suggests screening all adults with hypertension for primary aldosteronism with paired aldosterone and renin (conditional recommendation, low certainty). When testing capacity is limited, prioritize higher pretest probability: resistant hypertension, spontaneous or diuretic-associated hypokalemia, an adrenal incidentaloma, obstructive sleep apnea, early-onset hypertension or stroke, and a family history of primary aldosteronism. The 2025 AHA/ACC guideline recommends screening every adult with resistant hypertension regardless of potassium (Class of Recommendation 1, Level of Evidence B-NR), and the 2024 ESC guideline says screening should be considered in all adults with confirmed hypertension (Class IIa, Level B).
Screen on current medicines first
A first draw on usual treatment is reasonable, and preferred when changing drugs would endanger BP, volume, or potassium control. A positive screen despite renin-raising drugs (ACE inhibitors, ARBs, diuretics, SGLT2 inhibitors) remains meaningful. Mineralocorticoid receptor antagonists (MRAs) are the main exception the AHA/ACC guideline asks to pause before screening.
When the result can mislead
Hypokalemia lowers aldosterone (false negative): correct and repeat if suspicion persists. Beta blockers, clonidine, methyldopa, and NSAIDs lower renin (false positive). Estrogen-containing pills lower DRC. ACE inhibitors, ARBs, diuretics, MRAs, ENaC inhibitors, and SGLT2 inhibitors raise renin (false negative). In CKD, renin falls with nephron loss and aldosterone can be elevated, inflating false positives; renal artery stenosis raises renin.
Pearls & Pitfalls
Read three numbers, not one
A typical positive screen needs suppressed renin, inappropriately high aldosterone, and an elevated ratio. A ratio driven by a tiny renin with a low aldosterone is not a positive screen. Aldosterone 6 ng/dL with PRA 0.10 and aldosterone 24 ng/dL with PRA 0.40 both give an ARR of 60, but only the second fits primary aldosteronism.
Assay and units decide the threshold
Immunoassay aldosterone: suppressed renin plus aldosterone ≥10 ng/dL (277 pmol/L) and ARR >20 (ng/dL ÷ PRA ng/mL/h) or >70 (pmol/L ÷ DRC mU/L). LC-MS/MS aldosterone: ≥7.5 ng/dL (208 pmol/L), and the indicative ratio is about 25% lower. Renin is suppressed at PRA ≤1 ng/mL/h or DRC ≤8.2 mU/L. Do not convert DRC to PRA to borrow a threshold.
What changed from the 2016 approach
The fixed aldosterone floor of 15 ng/dL and the rule that every positive screen requires confirmatory testing are retired. Suppression testing is now reserved for intermediate probability when the patient wants to pursue surgery; a persuasive positive screen in someone who will not pursue surgery can go straight to MRA therapy with monitoring, and an overt pattern in resistant hypertension or hypokalemia can proceed to subtype evaluation.
Why Use It
Primary aldosteronism affects an estimated 5% to 14% of adults with hypertension in primary care and up to 30% in referral centers, yet fewer than 2% of eligible patients are tested in large health systems. At matched blood pressure it carries roughly 2.6-fold odds of stroke and 3.5-fold odds of atrial fibrillation versus essential hypertension, and it is specifically treatable: unilateral disease by adrenalectomy and bilateral disease by MRA titrated toward renin de-suppression. A careful ratio read, with its context, is the gate to that pathway.
Aldosterone-Renin Ratio (ARR) — Primary Aldosteronism Screening
Thresholds follow the 2025 Endocrine Society guideline and change with the aldosterone assay and renin measure. Results are a description of the screen for clinician interpretation.
⚕ Values per Adler GK et al., Primary Aldosteronism: An Endocrine Society Clinical Practice Guideline, J Clin Endocrinol Metab 2025;110(9):2453–2495. Ratio thresholds use “greater than”; aldosterone thresholds use “at or above”; renin suppression uses “at or below”. LC-MS/MS ratio thresholds are applied as 25% below immunoassay values, an approximation stated in the guideline. A description of the screen for clinicians; not a diagnosis or an instruction to change therapy.
Next Steps
- Pattern consistent with primary aldosteronism, surgery not wanted or unsuitable: discuss PA-directed MRA therapy (spironolactone first-line) with potassium and creatinine checks about 1 week after starting or titrating, then renin, electrolytes, and kidney function 2 to 3 months after each dose change; titrate toward a rise in renin if BP stays uncontrolled.
- Intermediate probability, surgery wanted: specialist-directed suppression testing (oral sodium loading, seated saline, or captopril challenge), choosing a test compatible with kidney function and volume status. Avoid saline loading with uncontrolled BP, heart failure, or advanced CKD.
- Overt pattern in resistant hypertension or hypokalemia, surgery wanted: proceed to adrenal CT, a 1-mg overnight dexamethasone suppression test if an adenoma is present, and adrenal vein sampling at an experienced center.
- Discordant or not consistent: review potassium, sodium intake, posture, timing, and interfering drugs; repeat under stable conditions, with a supervised withdrawal (2 weeks for ACE inhibitors, ARBs, beta blockers, central alpha-2 agonists; 4 weeks for MRAs, ENaC inhibitors, other diuretics) only when necessary and safe.
Patient and clinician guide: Primary aldosteronism: Could aldosterone be driving your high blood pressure?
Evidence & References
Formula
| Quantity | Formula |
|---|---|
| ARR with PRA | Aldosterone (ng/dL) ÷ PRA (ng/mL/h) |
| ARR with DRC | Aldosterone (pmol/L) ÷ DRC (mU/L) |
| Aldosterone conversion | ng/dL × 27.7 = pmol/L |
2025 Endocrine Society screening values
| Component | Immunoassay aldosterone | LC-MS/MS aldosterone |
|---|---|---|
| Renin suppressed | PRA ≤1 ng/mL/h or DRC ≤8.2 mU/L | |
| Aldosterone | ≥10 ng/dL (277 pmol/L) | ≥7.5 ng/dL (208 pmol/L) |
| ARR, PRA | >20 | about 25% lower (>15 used here) |
| ARR, DRC | >70 | about 25% lower (>52.5 used here) |
| Overt pattern | PRA <0.2 or DRC <2, and aldosterone >20 ng/dL (554 pmol/L) | PRA <0.2 or DRC <2, and aldosterone >15 ng/dL (416 pmol/L) |
DRC reported in ng/L uses assay-specific conversion factors, so this tool reports the ratio without a threshold-based pattern for that unit. Laboratory-validated cut points take precedence.
References
- Adler, G. K., Stowasser, M., Correa, R. R., et al. (2025). Primary aldosteronism: An Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism, 110(9), 2453–2495. https://doi.org/10.1210/clinem/dgaf284
- Jones, D. W., Ferdinand, K. C., Taler, S. J., et al. (2025). 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM guideline for the prevention, detection, evaluation and management of high blood pressure in adults. Hypertension, 82(10), e212–e316. https://doi.org/10.1161/HYP.0000000000000249
- Hundemer, G. L., Curhan, G. C., Yozamp, N., Wang, M., & Vaidya, A. (2018). Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: A retrospective cohort study. The Lancet Diabetes & Endocrinology, 6(1), 51–59. https://doi.org/10.1016/S2213-8587(17)30367-4
- Williams, T. A., Lenders, J. W. M., Mulatero, P., et al. (2017). Outcomes after adrenalectomy for unilateral primary aldosteronism. The Lancet Diabetes & Endocrinology, 5(9), 689–699. https://doi.org/10.1016/S2213-8587(17)30135-3
